SynthesisFrontiers in nutrition2024
Coffee and tea consumption and glioma risk: a meta-analysis of cohort studies.
Synthesis in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Research on the association between glioma risk and coffee and tea consumption remains inconclusive. This study seeks to present a meta-analysis of the relationship between coffee and tea intake and glioma risk. Method: Relevant cohort studies that collected coffee and tea exposure prospectively were identified through searches of the PubMed, Embase, and Scopus databases. Eligible studies included those providing adjusted relative risk estimates or hazard ratios (HRs) with 95% confidence intervals (CIs), or data sufficient for such calculations. Study quality was evaluated using the Newcastle-Ottawa Scale, while the GRADE system assessed the quality of evidence. The analysis explored glioma risk concerning the highest versus lowest levels of coffee and tea intake, supplemented by a dose-response evaluation using a one-stage robust error meta-regression model. Results: A total of nine studies, published between 2004 and 2020, were included. In a model comparing the highest and lowest levels of coffee and tea consumption, 3,896 glioma cases were identified among 2,648,468 participants. Correspondingly, the pooled HRs with 95% CIs were 0.98 (0.87-1.09) for coffee and 0.95 (0.86-1.06) for tea, respectively. Furthermore, no evidence of publication bias was detected for either beverage. The dose-response analysis indicated a near "L"-shaped relationship between tea consumption and glioma risk, with the most notable risk reduction observed in individuals consuming more than 2.5 cups of tea per day. However, additional tea intake beyond this threshold did not confer evident risk reduction. According to Grade scoring system, the quality of meta-evidence was classified as "very low" for coffee and "low" for tea. Conclusion: This meta-analysis provides evidence suggesting a potential inverse association between tea consumption and glioma risk, while no such association was observed for coffee consumption. Given that the evidence for coffee was classified as "very low" and for tea as "low," cautious interpretation of the findings is warranted, and further research is needed to validate these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.